Candida auris, a yeast infection that is resistant to multiple antimicrobial drugs, presents a serious global threat. The yeast causes invasive infections with high mortality and can persist on surfaces in healthcare environments – resulting in the spread of C. auris between patients in healthcare facilities.
The CDC first issued an alert in 2016 and last updated the case count on February 28th, 2019, whereby the total number of confirmed clinical cases in the US was at 587.
On March 29th, the CDC reported that most C. auris cases in the US have been detected in the New York City area, New Jersey, and the Chicago area. Across the globe there have been single and multiple cases of C. auris.:
Single cases: Austria, Belgium, Iran, Malaysia, the Netherlands, Norway, Switzerland, Taiwan, and the United Arab Emirates.
Multiple cases: Australia, Canada, China, Colombia, France, Germany, India, Israel, Japan, Kenya, Kuwait, Oman, Pakistan, Panama, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, the United Kingdom, the United States, Venezuela; in some of these countries, extensive transmission of C. auris has been documented in more than one hospital.
The CDC has provided this general information about Candida auris:
Healthcare facilities in several countries have reported that a type of yeast called Candida auris
has been causing severe illness in hospitalized patients. In some patients, this yeast can enter the bloodstream and spread throughout the body, causing serious invasive infections. This yeast often does not respond to commonly used antifungal drugs, making infections difficult to treat. Patients who have been hospitalized in a healthcare facility a long time, have a central venous catheter, or other lines or tubes entering their body, or have previously received antibiotics or antifungal medications, appear to be at highest risk of infection with this yeast.
Specialized laboratory methods are needed to accurately identify C. auris
. Conventional laboratory techniques could lead to misidentification and inappropriate management, making it difficult to control the spread of C. auris in healthcare settings.
Because of these factors, CDC is alerting U.S. healthcare facilities to be on the lookout for C. auris in their patients.
Why is CDC concerned about C. auris infections?
CDC is concerned about C. auris
for three main reasons:
- It is often multidrug-resistant, meaning that it is resistant to multiple antifungal drugs commonly used to treat Candida
- It is difficult to identify with standard laboratory methods, and it can be misidentified in labs without specific technology. Misidentification may lead to inappropriate management.
- It has caused outbreaks in healthcare settings. For this reason, it is important to quickly identify C. auris
in a hospitalized patient so that healthcare facilities can take special precautions to stop its spread.
What types of infections can C. auris cause?
C. auris has caused bloodstream infections, wound infections, and ear infections. It also has been isolated from respiratory and urine specimens, but it is unclear if it causes infections in the lung or bladder.
How is C. auris infection diagnosed?
Like other Candida infections, C. auris
infections are usually diagnosed by culture of blood or other body fluids. However, C. auris
is harder to identify from cultures than other, more common types of Candida. For example, it can be confused with other types of yeasts, particularly Candida haemulonii
. Special laboratory tests are needed to identify C. auris
. For more information, please see the Recommendations for Laboratorians and Health Professionals.
Who is at risk for infection from C. auris?
Limited data suggest that the risk factors for Candida auris
infections are generally similar to risk factors for other types of Candida infections. These risk factors include recent surgery, diabetes, broad-spectrum antibiotic and antifungal use. People who have recently spent time in nursing homes and have lines and tubes that go into their body (such as breathing tubes, feeding tubes and central venous catheters), seem to be at highest risk for C. auris
infection. Infections have been found in patients of all ages, from preterm infants to the elderly. Further study is needed to learn more about risk factors for C. auris
When was C. auris first reported?C. auris
was first identified in 2009 in Japan. Retrospective review of Candida strain collections found that the earliest known strain of C. auris
dates to 1996 in South Korea. CDC considers C. auris
an emerging pathogen because increasing numbers of infections have been identified in multiple countries since it was recognized.
How did C. auris get its name?
Auris is the Latin word for ear. Despite its name, C. auris
can also affect many other regions of the body and can cause invasive infections, including bloodstream infections and wound infections.
Where have C. auris infections occurred globally?C. auris
infections have been reported from over 20 countries, including the United States. Because identification of C. auris
requires specialized laboratory methods, infections likely have occurred in other countries but have not been identified or reported.
How did C. auris infection spread globally?
CDC conducted whole genome sequencing of C. auris
specimens from countries in the regions of eastern Asia, southern Asia, southern Africa, and South America. Whole genome sequencing produces detailed DNA fingerprints of organisms. CDC found that isolates within each region are quite similar to one another, but are relatively different across regions. These differences suggest that C. auris
has emerged independently in multiple regions at roughly the same time.
Would someone be likely to get a C. auris infection if they travel to any of these countries?
It is unlikely that routine travel to countries with documented C. auris
infections would increase the chance of someone getting sick from C. auris
. Infections have occurred primarily in patients who were already in the hospital for other reasons. People who travel to these countries to seek medical care or who are hospitalized there for a long time may have an increased risk for C. auris
Have C. auris infections occurred in the United States?
Cases of C. auris
infections have been reported in the United States. As laboratories continue to look for this fungus, it is likely that more cases will be reported.
What should someone do if they suspect they have a C. auris infection?
CDC recommends that anyone who believes they have any fungal infection or healthcare-associated infection see a healthcare provider.
Are C. auris infections treatable?
Most C. auris
infections are treatable with a class of antifungal drugs called echinocandins. However, some C. auris
infections have been resistant to all three main classes of antifungal medications, making them more difficult to treat. In this situation, multiple classes of antifungals at high doses may be required to treat the infection. Treatment decisions should be made in consultation with a healthcare provider experienced in treating patients with fungal infections.
Can a person die from infection with C. auris?
Yes. Invasive infections with any Candida species can be fatal. We don’t know if patients with invasive C. auris
infection are more likely to die than patients with other invasive Candida infections. Based on information from a limited number of patients, 30–60% of people with C. auris
infections have died. However, many of these people had other serious illnesses that also increased their risk of death.
How does C. auris spread?C. auris
can spread in healthcare settings through contact with contaminated environmental surfaces or equipment, or from person to person. More work is needed to further understand how it spreads.
How can the spread of C. auris be prevented?
Please see the Recommendations for Laboratorians and Health Professionals
What is CDC doing to address C. auris?
CDC is providing guidance for clinicians and infection control personnel. For more information, please see the Recommendations for Laboratorians and Health Professionals. CDC also is working with state and local health agencies, healthcare facilities, and clinical microbiology laboratories to ensure that laboratories are using proper methods to detect C. auris
and know the limitations of certain tests for detecting C. auris